Work

Phase 1 study of LOXO-101, a selective TRK inhibitor, in pediatric patients with cancer

Year: 2016

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdw368.50

Authors: T.W. Laetsch, R. Nagasubramanian, S.G. Dubois, L. Mascarenhas, D. Hawkins, N. Shukla, B. Turpin, S. Smith, M. Reynolds, S. Cruickshank, L. Donahue, M.C. Cox, A. Pappo

Institutions: The University of Texas Southwestern Medical Center, Nemours Children's Clinic, Boston Children's Hospital, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, University of Southern California, Children's Hospital of Los Angeles, Seattle Children's Hospital, Memorial Sloan Kettering Cancer Center, Cincinnati Children's Hospital Medical Center, Loxo Oncology at Lilly (United States), St. Jude Children's Research Hospital

Language: English

Topic: Sarcoma Diagnosis and Treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2587507633

FWCI:

Cites:

Cited by:

Related to: 10